How can Malaysian scientists contribute to vaccine innovation?

Question

Accepted Answer

Malaysian Scientists Can Contribute to Vaccine Innovation Through Research and Development

Malaysian scientists possess public health expertise that can be mobilised for vaccine innovation, with a particular focus on research and development (R&D) to produce Covid-19 vaccines. This initiative is considered crucial for preventing the further spread of the virus. The Ministry of Science, Technology and Innovation (MOSTI) will spearhead these R&D efforts, aiming for breakthroughs in scientific discoveries within the country.
Mobilising Public Health Expertise for Innovation

Malaysia has a pool of scientists with established expertise in public health, a critical area for developing and innovating vaccine technologies. The intention is to leverage this existing knowledge base to drive forward the creation of the nation's first Covid-19 vaccine. This mobilisation signifies a commitment to harnessing domestic scientific talent to achieve a significant public health goal.
Focusing R&D Efforts on Vaccine Production

The Ministry of Science, Technology and Innovation (MOSTI) has announced a strategic focus on research and development (R&D) specifically for the production of Covid-19 vaccines. This directive underscores the importance placed on developing indigenous vaccine manufacturing capabilities. The aim is to achieve self-sufficiency and potentially make scientific discoveries that contribute to global vaccine efforts.
Pursuing Bilateral Arrangements for Vaccine Technology

Beyond domestic capabilities, Malaysia plans to establish bilateral arrangements with countries that have already achieved success in Covid-19 vaccine production. Nations such as China, India, and Thailand are identified as potential collaborators. These partnerships are envisioned as a means to gain access to established technologies and accelerate the learning curve in vaccine manufacturing.
Developing Fill-and-Finish Capabilities

An initial step towards producing proprietary vaccines involves the establishment of fill-and-finish factories. This process is essential for the final stages of vaccine production, where the vaccine substance is bottled and prepared for distribution. However, the fill-and-finish technology requires thorough evaluation by the National Pharmaceutical Regulatory Division (NPRA) to ensure it meets stringent safety and efficacy standards before implementation.

Reading history

Hide →

This history is cleared when the page is closed.

How can Malaysian scientists contribute to vaccine innovation?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends